January 16, 2018 / 12:57 PM / 7 months ago

BRIEF-Tenax Therapeutics Announces Plan To Develop Levosimendan For A Pulmonary Hypertension Indication With No FDA Approved Therapies

Jan 16 (Reuters) - Tenax Therapeutics Inc:

* TENAX THERAPEUTICS ANNOUNCES PLAN TO DEVELOP LEVOSIMENDAN FOR A PULMONARY HYPERTENSION INDICATION WITH NO FDA APPROVED THERAPIES

* TENAX THERAPEUTICS - PHASE 2 TRIAL TO INVESTIGATE LEVOSIMENDAN IN PULMONARY HYPERTENSION-WHO GROUP 2 PATIENTS WITH PRESERVED EJECTION FRACTION

* TENAX THERAPEUTICS INC - PLANS TO INITIATE PHASE 2 TRIAL IN PH-HFPEF PATIENTS IN EARLY PART OF Q3 OF 2018

* TENAX THERAPEUTICS INC - ‍PRE-IND MEETING IS SCHEDULED WITH FDA TO DISCUSS DEVELOPMENT OF LEVOSIMENDAN IN PH-HFPEF IN COMING MONTHS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below